Moreover, they may be considered to be prognostic in several tumor types and may soon become part of clinical practice/diagnostic pathology; recent evidence suggests that new T-cell clones may enter the tumor to replace pre-existing, exhausted CD8+ T cells in response to IO therapy [80]. This evidence concerns the gene CD8A and neoplasm.